Drawing for VOYAGER

USPTO serial 90879826

VOYAGER

Reviewed by CopyMark Law Group

Status 730Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
HESIK, APRIL ANNE
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 730: Status 730 means you filed the first six-month extension to delay filing a Statement of Use after a Notice of Allowance. You must file a Statement of Use or another extension before the new deadline.

Need help with VOYAGER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*

Plus Government fees of $450

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Keith Toms, Esq.

Keith Toms, Esq. McCarter & English, LLP265 Franklin StreetBoston, MA 02110-3113United States

Goods and services

ClassDescriptionStatusFirst use
005Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies; gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising biological compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics for gene therapy or for the treatment of neurological diseases and disorders; Drug delivery agents comprising biological preparations in the nature of capsids that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics for gene therapy or for the treatment of neurological diseases and disordersACTIVE—
042Pharmaceutical research and development in the field of gene therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy; pharmaceutical research services; research and development of pharmaceutical preparations for gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development of platform technologies for genetic delivery of therapies and pharmaceuticals; research and development services in the field of platforms technologies for genetic delivery of therapies and pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development regarding the use of RNA-derived functional screening platforms to discover, research and develop novel capsids for genetic deliver of therapies and pharmaceuticals; research and development regarding the identification and targeting of specific cells and tissues for gene therapy deliveryACTIVE—
044Medical treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative diseaseACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 12, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 12, 2026EX1GSOU EXTENSION 1 GRANTED—
Aug 12, 2026EXT1SOU EXTENSION 1 FILED—
Aug 12, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 24, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 30, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 30, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 24, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 5, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 5, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Dec 5, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 5, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 5, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 9, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Sep 9, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jun 9, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 9, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 9, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 30, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Nov 20, 2024RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Oct 26, 2024RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jul 22, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 22, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 22, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Dec 5, 2023RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
May 19, 2023RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Nov 14, 2022GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 14, 2022GNSLLETTER OF SUSPENSION E-MAILED—
Nov 14, 2022CNSLSUSPENSION LETTER WRITTEN—
Nov 11, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 10, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 10, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 10, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 10, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 10, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2022DOCKASSIGNED TO EXAMINER—
Oct 4, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 16, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance